Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized three-arm phase II/III chemotherapy comparison in first-line metastatic breast cancer
NL-OMON29407Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2001
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in breast cancer comparing Epirubicin + docetaxel, Vinorelbine + docetaxel and Epirubicin + vinorelbine (3 arms). Primary endpoints: response rate and time to progression. Started Apr 2001; status: active, not recruiting.
02
Drugs
epirubicindocetaxelvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON29407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29407.